Healthy Volunteers Clinical Trial
Official title:
Double Blind, Randomized, Placebo-controlled Study of Safety, Tolerability, and Pharmacokinetics of Ascending Doses of XC7 After Single and Multiple Oral Administration in Healthy Volunteers
Verified date | September 2021 |
Source | NP Therapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A double-blind, randomized, placebo-controlled, Phase I clinical study of the safety, tolerability and pharmacokinetics (PK) of ascending doses of XC7 after single and multiple oral administration in healthy volunteers. It's planned to include sequentially 2 cohorts of 4 volunteers who will receive a single dose of XC7 (100 mg and 200 mg) or placebo (cohort ratio 3:1) and 1 cohort of 8 volunteers who will receive multiple doses of the XC7 (200 mg) or placebo during 14 days (cohort ratio 6:2).
Status | Completed |
Enrollment | 16 |
Est. completion date | April 9, 2021 |
Est. primary completion date | April 9, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: 1. Non-smoking men (nonsmokers at least within the last year before the screening) at the ages from 18 through 45; 2. Verified diagnosis "healthy" according to standard clinical, laboratory and instrumental methods of examination; 3. Body mass index from 18.5 to 30.0 kg/m2 with body weight of more than 45 kg and no more than 110 kg; 4. Negative result for alcohol vapor content in the exhaled air, narcotic substances in the urine; 5. Agreement to use adequate contraception methods during the study and 3 months after its completion: condoms with spermicide (foam, gel, cream, suppository); 6. Signed patient explanation sheet and informed consent for participation in the study. Exclusion Criteria: 1. Chronic diseases of the cardiovascular, bronchopulmonary, nervous, endocrine, musculoskeletal system, as well as the gastrointestinal tract, liver, kidneys, blood, mental illness, epilepsy or convulsive seizures; 2. Abnormal results of standard laboratory tests and investigations at the screening visit; 3. Gastrointestinal surgery (except for appendectomy) in the past medical history; 4. Systolic blood pressure of less than 90 mm Hg or above 139 mm Hg, diastolic blood pressure of less than 60 mm Hg or above 90 mm Hg, heart rate of less than 60 bpm or above 90 bpm - at screening; 5. Regular administration of drugs within 2 weeks prior to screening (including herbal agents and dietary supplements); 6. Use of drugs with significant effect on hemodynamics, hepatic function, etc. (e.g. barbiturates, omeprazole, cimetidine, etc.) within 30 days prior to screening; 7. Antibodies to HIV and hepatitis C, hepatitis B surface antigen, positive test for syphilis; 8. Unstable sleep architecture (e.g. night work, sleep disorders, insomnia, recently returned from another time zone, etc.), extreme physical activity (e.g. weight lifting); 9. Special diet (for example, vegetarian, vegan, low calorie (less than 1000 kcal/day)); 10. Signs of alcohol abuse (intake of more than 10 units of alcohol per week) or 50 ml of hard alcohol; drinking alcohol within 4 days prior to screening; 11. Signs of drug abuse; taking narcotic and psychotropic drugs (opiates/morphine, methamphetamine, amphetamine, cannabinoids/marijuana, cocaine, methadone, ecstasy, tricyclic antidepressants, barbiturates) at the moment and in the history; 12. burdened past allergic history; 13. Hypersensitivity to the components of the investigated drugs; 14. Blood/plasma donation (from 450 ml blood or plasma) within 2 months prior to screening; 15. Participation in other clinical studies within 3 months prior to screening; 16. Acute infectious diseases within 4 weeks prior to screening; 17. Inability to read or write; unwillingness to understand and follow the procedures of the study protocol; noncompliance with the drugs administration or procedures schedule, which according to the researchers may affect the study results or the volunteer safety and prevent the further participation of the volunteer in the study; any other associated medical or serious mental conditions that make the volunteer inadequate for participation in the clinical study and restrict the validity of informed consent or may affect the volunteer's ability to participate in the study. |
Country | Name | City | State |
---|---|---|---|
Russian Federation | Federal State Autonomous Educational Institution of Higher Education "The First Moscow State Medical University named after I.M. Sechenov" of the Ministry of Health of the Russian Federation | Moscow |
Lead Sponsor | Collaborator |
---|---|
NP Therapeutics |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Adverse events (AEs) per treatment arm | Adverse events will be classified according to CTCAE ver 4.03. Adverse events will be summarized descriptively by treatment arm. Verbatim terms will be mapped to preferred terms and organ systems using the current Medical Dictionary for Regulatory Activities version. | Day -7 (7 days before first dose) - Day 58 | |
Secondary | Pharmacokinetics of XC7 by assessing AUC0-inf | Area under the curve "concentration of the drug-time" from the time of administration of the drug till infinity. | Day 1 - Day 4 | |
Secondary | Pharmacokinetics of XC7 by assessing Cmax | Maximum plasma concentration | Day 1 - Day 4 | |
Secondary | Pharmacokinetics of XC7 by assessing AUC0-t | Area under the curve "concentration of the drug-time" from the time of administration of the drug till the time (t) the last blood sampling | Day 1 - Day 4 | |
Secondary | Pharmacokinetics of XC7 by assessing Tmax | Time to maximum drug concentration in the blood plasma administration | Day 1 - Day 4 | |
Secondary | Pharmacokinetics of XC7 by assessing T1/2 | Terminal elimination half-life | Day 1 - Day 4 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |